title: Combined Therapy of Gastrointestinal Stromal Tumors.
abstract: Radical surgery is the mainstay of therapy for primary resectable, localized gastrointestinal stromal tumors (GIST). Nevertheless, approximately 40% to 50% of patients with potentially curative resections develop recurrent or metastatic disease. The introduction of imatinib mesylate has revolutionized the therapy of advanced (inoperable and/or metastatic) GIST and has become the standard of care in treatment of patients with advanced GIST. This article discusses the proper selection of candidates for adjuvant and neoadjuvant treatment in locally advanced GIST, exploring the available evidence behind the combination of preoperative imatinib and surgery.
authors: Department of Soft Tissue, Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology, Roentgena 5, Warsaw 02-781, Poland. Electronic address: piotr.rutkowski@coi.pl.
authors: Piotr
authors: P
authors: Rutkowski
authors: Department of Surgical Oncology, University Hospitals Gasthuisberg Leuven, Herestraat 49, Leuven 3000, Belgium.
authors: Daphne
authors: D
authors: Hompes
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D017024:Chemotherapy, Adjuvant; D019468:Disease Management; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000556:secondary*; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local; D010879:Piperazines; D011743:Pyrimidines; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate
keywords: Adjuvant therapy; Gastrointestinal stromal tumor; Imatinib; Neoadjuvant therapy; Surgery